Abstract
Phosphatase and tensin homolog (PTEN) is a negative regulator of the phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT) signaling pathway and a potent tumor suppressor in many types of cancer. To test a tumor suppressive role for PTEN in pre-B acute lymphoblastic leukemia (ALL), we induced Cre-mediated deletion of Pten in mouse models of pre-B ALL. In contrast to its role as a tumor suppressor in other cancers, loss of one or both alleles of Pten caused rapid cell death of pre-B ALL cells and was sufficient to clear transplant recipient mice of leukemia. Small-molecule inhibition of PTEN in human pre-B ALL cells resulted in hyperactivation of AKT, activation of the p53 tumor suppressor cell cycle checkpoint and cell death. Loss of PTEN function in pre-B ALL cells was functionally equivalent to acute activation of autoreactive pre–B cell receptor signaling, which engaged a deletional checkpoint for the removal of autoreactive B cells. We propose that targeted inhibition of PTEN and hyperactivation of AKT triggers a checkpoint for the elimination of autoreactive B cells and represents a new strategy to overcome drug resistance in human ALL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Osmond, D.G. Proliferation kinetics and the lifespan of B cells in central and peripheral lymphoid organs. Curr. Opin. Immunol. 3, 179–185 (1991).
Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374–1377 (2003).
Keenan, R.A. et al. Censoring of autoreactive B cell development by the pre-B cell receptor. Science 321, 696–699 (2008).
Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573–586 (2009).
Ramadani, F. et al. The PI3K isoforms p110-α and p110-δ are essential for pre-B cell receptor signaling and B cell development. Sci. Signal. 3, ra60 (2010).
Deau, M.C. et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J. Clin. Invest. 124, 3923–3928 (2014).
Vivanco, I. & Sawyers, C.L. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat. Rev. Cancer 2, 489–501 (2002).
Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177–183 (2004).
Gutierrez, A. et al. High frequency of PTEN, PI3K and AKT abnormalities in T cell acute lymphoblastic leukemia. Blood 114, 647–650 (2009).
Lesche, R. et al. Cre-loxP–mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32, 148–149 (2002).
Zhang, J. et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 118, 3080–3087 (2011).
Guo, B., Kato, R.M., Garcia-Lloret, M., Wahl, M.I. & Rawlings, D.J. Engagement of the human pre-B cell receptor generates a lipid raft–dependent calcium signaling complex. Immunity 13, 243–253 (2000).
Okada, T., Maeda, A., Iwamatsu, A., Gotoh, K. & Kurosaki, T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 13, 817–827 (2000).
Anzelon, A.N., Wu, H. & Rickert, R.C. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat. Immunol. 4, 287–294 (2003).
Aiba, Y., Kameyama, M., Yamazaki, T., Tedder, T.F. & Kurosaki, T. Regulation of B cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 111, 1497–1503 (2008).
Tesio, M. et al. Pten loss in the bone marrow leads to G-CSF–mediated HSC mobilization. J. Exp. Med. 210, 2337–2349 (2013).
Peng, C. et al. PTEN is a tumor suppressor in CML stem cells and in BCR-ABL–induced leukemias in mice. Blood 115, 626–635 (2010).
Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275, 1943–1947 (1997).
Gutierrez, A. et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J. Exp. Med. 208, 1595–1603 (2011).
Lenz, G. et al. Molecular subtypes of diffuse large B cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. USA 105, 13520–13525 (2008).
Miletic, A.V. et al. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J. Exp. Med. 207, 2407–2420 (2010).
Pfeifer, M. et al. PTEN loss defines a PI3K-AKT pathway–dependent germinal center subtype of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 110, 12420–12425 (2013).
Tibes, R. et al. Reverse-phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512–2521 (2006).
Roman-Gomez, J. et al. Lack of CpG island methylator phenotype defines a clinical subtype of T cell acute lymphoblastic leukemia associated with good prognosis. J. Clin. Oncol. 23, 7043–7049 (2005).
Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).
Köhler, F. et al. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity 29, 912–921 (2008).
Xie, H., Ye, M., Feng, R. & Graf, T. Stepwise reprogramming of B cells into macrophages. Cell 117, 663–676 (2004).
Shackelford, D.B. et al. mTOR and HIF-1α–mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 106, 11137–11142 (2009).
Düvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171–183 (2010).
Rosivatz, E. et al. A small-molecule inhibitor for phosphatase and tensin homolog deleted on chromosome 10 (PTEN). ACS Chem. Biol. 1, 780–790 (2006).
Li, Y. et al. Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. Blood 117, 6702–6713 (2011).
Chen, Z. et al. Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia. Nature 521, 357–361 (2015).
Shojaee, S. et al. Erk negative feedback control enables pre B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell 28, 114–128 (2015).
Kharas, M.G. et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K-mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest. 118, 3038–3050 (2008).
Khulan, B. et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res. 16, 1046–1055 (2006).
Acknowledgements
We would like to thank L.M. Staudt (National Cancer Institute), D.A. Fruman (University of California, Irvine), T. Kurosaki (World Premier International (WPI) Immunology Frontier Research Center), S. Li (Dana-Farber Cancer Institute) and A. Weiss (University of California, San Francisco) for comments and critical discussion of this study. This work is supported by the US National Institutes of Health (NIH) and the National Cancer Institute through grants R01CA137060 (M.M.), R01CA139032 (M.M.), R01CA157644 (M.M.), R01CA169458 (M.M.) and R01CA172558 (M.M.), the William Lawrence and Blanche Hughes Foundation (M.M.), the California Institute for Regenerative Medicine (CIRM; grant TR2-01816; M.M.) and Bloodwise (M.M.). T.G.G. is the recipient of a Research Scholar Award from the American Cancer Society (award RSG-12-257-01-TBE), an Established Investigator Award from the Melanoma Research Alliance (award 20120279), and is supported by NIH–National Center for Advancing Translational Science (NCATS) UCLA CTSI grant UL1TR000124. M.M. is a Scholar of the Leukemia and Lymphoma Society and a Senior Investigator of the Wellcome Trust.
Author information
Authors and Affiliations
Contributions
S.S. and M.M. designed experiments and interpreted data; M.M. conceived the study, obtained funding, coordinated collaborations and wrote the paper; S.S., L.N.C., M.B., V.C., K.N.C. and H.G. performed experiments and analyzed data; Y.H.Q., A.M. and S.M.K. provided and characterized patient samples or cell lines and clinical outcome data; H.W. provided important reagents and mouse samples; M.D.v.M., T.E., A.H., G.C., S.M.K., T.G.G. and H.J. provided conceptual input to the design of the study.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–10 and Supplementary Tables 1–5 (PDF 3501 kb)
Rights and permissions
About this article
Cite this article
Shojaee, S., Chan, L., Buchner, M. et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med 22, 379–387 (2016). https://doi.org/10.1038/nm.4062
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4062
This article is cited by
-
RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis
Signal Transduction and Targeted Therapy (2023)
-
Effect of the traditional Chinese medicine Pinggan-Qianyang decoction on SIRT1–PTEN signaling in vascular aging in spontaneously hypertensive rats
Hypertension Research (2021)
-
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
Nature Communications (2021)
-
Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia
Nature Communications (2020)
-
Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma
Leukemia (2020)